CytoMed Therapeutics Ltd

GDTC

Company Profile

  • Business description

    CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

  • Contact

    1 Commonwealth Lane
    No. 08-22 One Commonwealth
    Singapore149544
    SGP

    T: +65 62507738

    https://w2.cytomed.sg

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    42

Stocks News & Analysis

stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.
stocks

Turnaround progressing for ASX share

Margins have rebased by shares are undervalued.
stocks

Investors overlooking ASX share’s potential

International expansion is a distraction from valuable local business.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,732.8085.70-0.97%
CAC 407,952.55129.72-1.61%
DAX 4023,950.57505.69-2.07%
Dow JONES (US)49,526.17537.29-1.07%
FTSE 10010,195.37177.56-1.71%
HKSE25,513.06449.67-1.73%
NASDAQ26,225.14410.08-1.54%
Nikkei 22560,843.09566.20-0.92%
NZX 50 Index12,779.82185.19-1.43%
S&P 5007,408.5092.74-1.24%
S&P/ASX 2008,503.9074.00-0.86%
SSE Composite Index4,119.8615.53-0.38%

Market Movers